N1-Ethylcarbamoyl Cabergoline

• CAT Number: R024822
• CAS Number: 126554-50-5
• Molecular Formula: C29H42N6O3
• Molecular Weight: 522.694
• Purity: ≥95%
• Synonyms: (8β)-N8-[3-(Dimethylamino)propyl]-N1-ethyl-N8-[(ethylamino)carbonyl]-6-(2-propen-1-yl)-ergoline-1,8-dicarboxamide; (8β)-N8-[3-(dimethylamino)propyl]-N1-ethyl-N8-[(ethylamino)carbonyl]-6-(2-propenyl)–ergoline-1,8-dicarboxamide
• Storage: Desiccate at -20C
• IUPAC Name: (6aR,9R,10aR)-9-N-[3-(dimethylamino)propyl]-4-N-ethyl-9-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-4,9-dicarboxamide
• InChI: InChI=1S/C29H42N6O3/c1-6-13-33-18-21(27(36)34(28(37)30-7-2)15-10-14-32(4)5)16-23-22-11-9-12-24-26(22)20(17-25(23)33)19-35(24)29(38)31-8-3/h6,9,11-12,19,21,23,25H,1,7-8,10,13-18H2,2-5H3,(H,30,37)(H,31,38)/t21-,23-,25-/m1/s1
• InChIKey: MNAGYQBVKIBCGP-GZGNHOFSSA-N
• SMILES: CCNC(=O)N1C=C2CC3C(CC(CN3CC=C)C(=O)N(CCCN(C)C)C(=O)NCC)C4=C2C1=CC=C4

N1-Ethylcarbamoyl Cabergoline is a synthetic derivative of cabergoline, used in pharmaceutical research for its potential dopamine agonist properties. This compound is studied for its efficacy in treating disorders like Parkinson’s disease and hyperprolactinemia. Known for its enhanced stability and bioavailability, it contributes to developing advanced therapies, improving patient outcomes in neurodegenerative and hormonal conditions.